Zepbound Samples: Savings Card, LillyDirect & Coupons (2026)
Zepbound is Eli Lilly's tirzepatide product for chronic weight management — the same molecule as Mounjaro but dosed and labeled for obesity care. It landed in late 2023, hit the FDA shortage list almost immediately, and spent most of 2024 and 2025 as the single most supply-constrained GLP-1 on the market.
In 2026 the supply picture is finally stable, and Lilly has built out two consumer-facing programs that make Zepbound much more accessible than Wegovy was at this stage of its lifecycle. The Zepbound savings card functions like the Wegovy card — commercial insurance plus manufacturer copay assistance. LillyDirect, Lilly's direct-to-patient pharmacy, sells Zepbound vials (the lower-cost presentation) at a deliberately aggressive cash-pay rate for patients without coverage.
We've mapped out what Zepbound actually costs in 2026, which path to pick based on your coverage, and how to avoid the compounded-tirzepatide providers whose supply claims don't match what a state board of pharmacy can verify.
What's actually available: Zepbound samples in 2026
Three paths for people typing “zepboundsamples” — what they actually mean, typical cost, and who each path fits.
| Path | What it actually is | Typical cost | Best for |
|---|---|---|---|
| Zepbound savings card | Manufacturer copay card for commercially insured patients whose plan covers Zepbound. | $25 / 28-day supply | Patients whose employer plan covers weight-loss drugs |
| LillyDirect vials (cash) | Lilly's direct-to-patient pharmacy selling single-dose vials at cash rate. | $399–$549 / 28-day supply | Uninsured or non-covered patients who want brand-name Zepbound |
| Compounded tirzepatide | Not Zepbound — same molecule from a 503A/503B pharmacy, narrowing availability after FDA's shortage delisting. | $249–$449 / month all-in | Cash-pay patients willing to use a licensed compounding pharmacy |
How Zepbound sample programs actually work
How the Zepbound savings card stacks vs. Wegovy's
Lilly's Zepbound savings card is structurally similar to Novo's Wegovy card but with slightly different mechanics. Eligible commercially insured patients whose plan covers Zepbound pay as little as $25 per 28-day supply. Patients whose plan doesn't cover it still get a discount — roughly $463 off the retail price — bringing the cash equivalent to under $650/month. Federal plan enrollees are excluded by the same Anti-Kickback Statute that excludes all manufacturer cards.
LillyDirect vials: the strategic cash-pay play
LillyDirect sells Zepbound in single-dose vials (not the auto-injector pen) for $399 at the starter 2.5 mg dose, up to $549 at the 10 mg dose. The 15 mg maintenance dose is not yet available through LillyDirect at the vial rate. Lilly's strategy is explicit: push the cash floor down hard enough that the compounded tirzepatide market has a harder time competing. For uninsured patients who want the brand-name drug, LillyDirect is typically 50–65% cheaper than retail pharmacies.
Why compounded tirzepatide got harder in 2025
When the FDA removed tirzepatide from the shortage list in October 2024, 503A compounding pharmacies lost the primary legal basis for large-scale tirzepatide production. Smaller-scale personalization under Section 503A still exists where clinically justified, and 503B outsourcing facilities operate under a different regulatory framework. The practical effect: fewer reputable compounded tirzepatide providers in 2026 than in 2024, and more scrutiny of the ones that remain. Verify any provider's state board license before purchasing.
Telehealth providers that handle Zepbound workflow
Ro, Found, WeightWatchers Clinic, and Hims all maintain Zepbound workflows with Lilly's savings card integration and LillyDirect referral paths. The value these providers add is primarily in the prior-authorization cycle and in handling titration coaching when GI side effects appear at week 4–8 dose escalations. Provider quality varies — look for ones with state-licensed clinicians rather than a patchwork of contract prescribers.
Zepbound is the first obesity drug where the manufacturer's cash-pay price was designed to be the floor, not the ceiling — that's the whole strategic point of LillyDirect.
Top providers offering Zepbound or the compounded alternative
Providers we've verified currently support a clinically appropriate Zepbound path. Pricing and availability vary by state. Every link is an affiliate link tracked through Impact Engine — see our disclosure.
| Rank | Provider | Best for | Sample type | Editor | Readers | Action |
|---|---|---|---|---|---|---|
| #1 | Henry Meds Compounded Semaglutide · Compounded Tirzepatide | best-for-compounded | telehealth | 4.6 / 5 | — | See offer |
| #2 | Mochi Health Compounded Semaglutide · Compounded Tirzepatide | best-for-clinical-support | telehealth | 4.4 / 5 | — | See offer |
| #3 | Ro Body Semaglutide · Tirzepatide | best-for-branded-rx | telehealth | 4.3 / 5 | — | See offer |
| #4 | Sesame Care Semaglutide · Tirzepatide | best-for-one-time-visit | telehealth | 4.2 / 5 | — | See offer |
| #5 | Found Semaglutide · Tirzepatide | best-for-insurance-coverage | telehealth | 4.0 / 5 | — | See offer |
| #6 | LifeMD Semaglutide · Tirzepatide | best-for-regulated-provider | telehealth | 4.0 / 5 | — | See offer |
| #7 | WeightWatchers Clinic Semaglutide · Tirzepatide | best-for-lifestyle-bundle | telehealth | 3.9 / 5 | — | See offer |
Henry Meds
Flat-rate compounded GLP-1 with a free telehealth consult to see if you qualify.
- ✓ Free intake consult
- ✓ Flat monthly price, no insurance needed
- ✓ No long-term contract
- − Not available in all states
- − Supply constraints during GLP-1 shortages
- − Compounded only (no branded Ozempic/Wegovy)
Mochi Health
Compounded GLP-1 with a dietitian-led program and insurance-billing option.
- ✓ Includes dietitian visits
- ✓ Insurance billing available
- ✓ Strong clinical team
- − Higher price than cash-only peers
- − Intake can take several days
- − US only
Ro Body
Major branded-Rx telehealth with a dedicated GLP-1 weight-loss program.
- ✓ Branded Wegovy / Zepbound when available
- ✓ Insurance coordination support
- ✓ Established national brand
- − Higher monthly cost
- − Intake and shipping slower than lean competitors
- − Not all medications in stock in all states
Sesame Care
A la carte telehealth where you pay per visit and get real GLP-1 prescriptions at list pricing.
- ✓ No subscription or recurring fee
- ✓ Pay once for the consult
- ✓ Use your own pharmacy + GoodRx
- − Medication cost is separate
- − No built-in coaching or support
- − Availability varies by state
Found
Weight-loss program that coordinates branded and compounded GLP-1 based on what your insurance covers.
- ✓ Handles prior authorizations
- ✓ Branded or compounded based on coverage
- ✓ Integrated coaching
- − Cost higher than cash-only peers
- − PA process can take weeks
- − Program requires 3-month commitment
Zepbound cost in 2026: every legitimate price path
What you'll actually pay depends on insurance, the path you take, and whether you stay on the brand-name drug. Here's the real money:
| Path | First month | Ongoing | Notes |
|---|---|---|---|
| Savings card (commercial coverage) | $25 | $25/mo until annual cap | Covered-plan patients only; federal plans excluded. |
| Savings card (commercial, no coverage) | ~$650 | ~$650/mo | ~$463 off retail for commercially insured but non-covered patients. |
| LillyDirect vials (cash) | $399 | $399–$549/mo | Dose-tiered; 2.5/5 mg at $399, 7.5/10 mg at $499–$549. |
| Retail cash price | $1,086 | $1,086/mo | Pen formulation without insurance or savings card. |
| Compounded tirzepatide | $249–$349 | $349–$449/mo | Narrowing market; verify pharmacy licensing. |
What to expect on Zepbound: your first weeks
Zepbound titration is monthly: start at 2.5 mg weekly for 4 weeks, step up to 5 mg, then 7.5, 10, 12.5, and 15 mg. Most patients stabilize at 10 or 15 mg for maintenance. The FDA-approved schedule is aggressive compared to some telehealth programs that extend titration to reduce GI side effects.
GI side effects in the first month — nausea, constipation, reflux — are common and almost always most intense at each dose escalation. About 10–15% of patients discontinue in the first 12 weeks in clinical trials; most of that drop-off is GI tolerability, not efficacy failure.
Weight response shows up earlier on tirzepatide than on semaglutide in head-to-head observational data. Expect meaningful appetite suppression from week two, visible weight change by week 6–8, and the bulk of the clinical trial's 20.9% mean loss accumulating between weeks 20 and 72.
Clinical evidence behind Zepbound
Zepbound was approved by the FDA in November 2023 based on the SURMOUNT trial program. SURMOUNT-1 (published in NEJM, 2022) showed mean weight loss of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg weekly doses over 72 weeks, compared to 3.1% on placebo. This exceeds the STEP-1 results for semaglutide and makes tirzepatide the most effective pharmaceutical weight-loss agent the FDA has approved to date. SURMOUNT-2 extended the indication to patients with overlapping Type 2 diabetes in 2024.
Zepboundside effects & who shouldn't take it
This is not medical advice. Discuss every medication decision with a licensed clinician who knows your full medical history.
Common side effects
- •Nausea (very common, usually peaks at dose escalations)
- •Diarrhea or constipation
- •Vomiting at dose escalation
- •Decreased appetite (typically intended; occasionally excessive)
- •Injection-site reactions
- •Rare but serious: pancreatitis, gallbladder disease, medullary thyroid carcinoma warning
Who shouldn't take Zepbound
- •Personal or family history of medullary thyroid carcinoma (MTC)
- •Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- •Pregnancy or plans to become pregnant within 2 months
- •History of severe pancreatitis
- •Current eating disorder not in remission
Eligibility for Zepbound
- •Adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
- •No contraindications (thyroid carcinoma history, MEN 2, severe pancreatitis)
- •Commercial insurance for savings card eligibility
- •Not required: specific prior weight-loss attempt history
Zepbound samples: frequently asked
Are Zepbound samples actually free?
Eli Lilly does not distribute free consumer-facing Zepbound samples. The closest equivalents are the savings card ($25/month for eligible commercially insured patients) and LillyDirect's $399–$549/month vial pricing for cash-pay patients.
How much is Zepbound without insurance?
LillyDirect sells single-dose vials at $399 for the 2.5 mg and 5 mg starter doses, and $499–$549 for 7.5 mg and 10 mg. Retail pharmacies charge around $1,086 for the pen formulation.
What's the difference between Zepbound and Mounjaro?
Same molecule (tirzepatide), different FDA labels. Zepbound is approved for chronic weight management. Mounjaro is approved for Type 2 diabetes. Insurance typically treats them as separate products on the formulary.
Can I switch from compounded tirzepatide to Zepbound?
Yes, with a new prescription from your clinician. Most clinicians transition patients at an equivalent dose; some slow the titration by one step to ease the switch. Pharmacy-to-pharmacy, it's a fresh Rx and fresh dispensing workflow.
How fast can I start Zepbound?
LillyDirect ships in 3–5 business days once a prescription is written. Telehealth providers complete intake in 24–72 hours in most states. Insurance-covered paths depend on the prior-authorization cycle, typically 7–14 days with a provider who knows the PA language.
What BMI do I need for Zepbound?
BMI ≥30 qualifies alone. BMI ≥27 qualifies with at least one weight-related comorbidity (hypertension, dyslipidemia, Type 2 diabetes, obstructive sleep apnea).
Is Zepbound more effective than Wegovy?
In trial results (not head-to-head trials), Zepbound at 15 mg showed 20.9% mean weight loss at 72 weeks vs. Wegovy's 14.9% at 68 weeks. Real-world outcomes vary by patient and by tolerability at each dose step.
Does LillyDirect require insurance verification?
No. LillyDirect is specifically a cash-pay channel — the $399–$549 vial pricing applies regardless of insurance status. A valid prescription is required.
Can Medicare patients use the Zepbound savings card?
No. Federal law excludes Medicare, Medicaid, VA, and Tricare enrollees from manufacturer copay assistance. Lilly's Patient Assistance Program is a separate application for eligible uninsured or underinsured patients.
Do I have to use the pen, or can I use vials?
Both are FDA-approved. The pen is the original auto-injector presentation. LillyDirect's vials require you to draw the dose with a separate syringe — cheaper, but with a small learning curve. Most telehealth programs provide injection coaching either way.